Moderna (MRNA) shares surged 7.38% to $259.25 following a robust third-quarter performance characterized by significant revenue growth and a return to profitability. The company reported quarterly revenue of $1.3 billion, representing a 29% year-over-year increase driven primarily by rising international vaccine sales and government agreements....
Bullish Signals
Stock jumped 7.38% to $259.25 on strong Q3 revenue growth of 29%.
Swung to $162M quarterly profit with $0.38 EPS, returning to profitability.
Raised 2026 revenue forecast to 15%-25%, above prior max guidance of 10%.
Increased year-end cash forecast to $8.1B-$8.3B from prior projection of $4.7B-$5.2B.
Phase 3 melanoma data showed 42% drop in recurrence or death risk.
Moderna stock surged approximately 9% on Friday, reaching a price of $149, driven primarily by a significant Phase 3 clinical trial win for its personalized mRNA cancer vaccine in partnership with Merck. The trial demonstrated that the vaccine, known as intismeran autogene (mRNA-4157), significantly reduced...
Bullish Signals
Stock surged 9% to $149 on Phase 3 melanoma win.
FDA approved mFLUSIVA flu vaccine and updated COVID-19 shots.
Argus upgraded to Buy with $180 price target.
Personalized cancer tech opens billion-dollar treatment era.
Moderna (NASDAQ: MRNA) shares surged approximately 90% in pre-market trading on Wednesday following the announcement of positive Phase 3 clinical trial results for its personalized mRNA-based cancer vaccine, intismeran (mRNA-4157), developed in partnership with Merck. The stock, which had closed the previous session at roughly...
Bullish Signals
Stock surged 90% to $120 on positive Phase 3 data.
Trial met primary endpoint with significant improvement over Keytruda.
First successful Phase 3 study of individualized neoantigen therapy.
Enrolled 1,100 patients with no new safety concerns.
Validates oncology strategy and strengthens pipeline beyond COVID.
Moderna (MRNA) shares surged to a near five-year high of $280.80 after the biotechnology company reported its first profitable quarter in two years. The third-quarter net income reached $162 million, or $0.38 per share, driven by a 29% revenue increase to $1.31 billion supported by...
Bullish Signals
Q3 net income hit $162M, reversing prior year loss.
Moderna Inc. (NASDAQ:MRNA) shares surged to a new three-year high of $176.86, driven by investor anticipation of upcoming clinical trial data for its melanoma treatment candidate, intismeran autogene. The stock traded above $174 as the market reacted positively to the prospect of significant pipeline updates...
Bullish Signals
Stock hit $176.86 three-year high.
Phase 3 trial met primary endpoint.
First positive Phase 3 combo therapy result.
Hedge fund holdings rose 10% to $1.5B.
Intismeran targets 112,000 annual US melanoma cases.
Moderna (MRNA) stock delivered a massive 677.7% return over the twelve months ending October 27, 2026, significantly outperforming the S&P 500. This surge was driven by the successful market adoption of its next-generation COVID vaccine, mNEXSPIKE, which captured approximately 24% of the U.S. retail COVID...
Bullish Signals
Stock surged 677.7% over trailing twelve months ending Oct 27, 2026.
FDA approved mRNA flu vaccine for adults 50+ in August 2026.
mNEXSPIKE achieved 24% U.S. retail COVID vaccine market share first season.
Revenue grew to $143 million Q2 2026, up 4.4% year-over-year.
Management forecasts up to 10% revenue growth for 2026.
Bearish Signals
COVID revenue fell 41.3% as core business shrank.
Abandoned CMV vaccine after late-stage trial failure.
Moderna (NASDAQ:MRNA) shares surged approximately 14.2% to close at $225.00 on October 9, 2026, reaching a multi-year high driven by two distinct catalysts. The primary driver was the company's re-inclusion into the Nasdaq-100 Index (NDX), which mandates automatic buying by over 200 investment products managing...
Bullish Signals
Shares surged 14.2% to $225.00 after Nasdaq-100 re-inclusion.
Merck collaboration met primary goal for melanoma recurrence delay.
Positioned to benefit from NIH national cancer vaccine initiative.
mRNA therapy validated by effective tumor recurrence delay results.
Lung, kidney, and bladder cancer trial data coming Oct 24.
Bearish Signals
Shares overvalued after 600% YTD run; Citi needs $26B sales to justify.
Rally driven by index rebalancing; price support may weaken soon.
Clinical trial resultsDrug approvalNew drug indicationAI-generated analysis
Moderna (MRNA) and Merck announced a landmark breakthrough in August regarding their therapeutic cancer vaccine, intismeran autogene (INT), which combines mRNA technology with Keytruda. Phase 3 study results showed the combination significantly reduced the risk of melanoma recurrence or death by 49% over five years...
Bullish Signals
Phase 3 data shows 49% melanoma recurrence risk reduction vs Keytruda.
Moderna (MRNA) experienced extreme stock volatility following the release of Phase 3 trial data for its mRNA cancer vaccine candidate, intismeran autogene (mRNA-4157). The stock surged 177% on Wednesday after the combination therapy met key goals in a study of patients with advanced melanoma, showing...
Bullish Signals
mRNA cancer vaccine cut recurrence/death 49% vs KEYTRUDA in melanoma.
Nine studies validate oncology platform across multiple cancer types.
Validated franchise transforms company from respiratory-vaccine to major oncology player.
Bearish Signals
Shares crashed 20% after investors took profits.
Faces $950M litigation settlement due in July 2026.
Moderna Inc. (NASDAQ: MRNA) shares surged approximately 6.21% on Tuesday, June 23, 2026, driven by a unanimous FDA advisory committee vote favoring its mRNA-1010/mFLUSIVA seasonal flu vaccine for adults aged 50 and older. The stock climbed from roughly $47 to $63 over the preceding month,...
Bullish Signals
FDA voted 9-0 to support Moderna's flu vaccine, reducing regulatory risk.
Stock surged 34% from $47 to $63, showing strong investor confidence.
Company holds $5.2B cash against $4.08B liabilities for ample liquidity.
New three-franchise model signals strategic shift beyond the COVID one-hit-wonder.
German manufacturing expansion builds independent global capacity for future vaccines.
Moderna (MRNA) stock has surged for a fifth consecutive day following the publication of FDA briefing documents indicating that immunogenicity data from its mFlusiva flu shot may support effectiveness in adults aged 65 and older. This represents a significant regulatory shift, as the FDA had...
Bullish Signals
FDA documents suggest favorable review of mFlusiva flu vaccine.
Moderna reversed FDA rejection after amending trial design.
mFlusiva would be first mRNA-based seasonal flu vaccine in US.
Jefferies projects $750 million combined sales by 2030.
EU approved mCOMBRIAX, first global flu-plus-COVID combo vaccine.
Ester Banque appointed Chief Commercial Officer for launches.
Pivotal cancer and rare disease data expected in 2026.
Bearish Signals
Limited to one flu season study.
Excluded immunocompromised and frail older adults.
Moderna (MRNA) shares surged 17.4% in the afternoon session after the company settled a long-running patent dispute with Arbutus Biopharma and Genevant Sciences. The agreement, valued at up to $2.25 billion, resolves legal uncertainties surrounding the technology used in its COVID-19 vaccine and eliminates future...
Moderna shares dropped as much as 25% on Thursday following a leak of partial data regarding its personalized cancer vaccine, intismeran autogene, developed in partnership with Merck. Despite the stock decline, the full data released later that day showed positive results relative to Wall Street...
Bullish Signals
Vaccine + Keytruda cut melanoma recurrence/death risk by 42%.
82% of patients alive cancer-free at two years vs 70% alone.
Treatment showed mild toxicity compared to standard cancer therapies.
Six-month regimen reduced recurrence/death risk by 58%.
Analysts view data as strong, dismissing stock drop as overreaction.
Bearish Signals
Shares fell 25% after partial cancer vaccine data leak.
Long-term survival benefit of treatment remains undetermined.
Moderna (MRNA) shares fell nearly 6% in premarket trading after Citigroup downgraded the biotechnology company from 'Hold' to 'Sell' and raised its price target to $80 from $60. The downgrade stems from concerns that Moderna's current valuation is difficult to justify given its lower expected...
Bullish Signals
Shares rallied 223% after intismeran autogene late-stage trial results.
Oncology program with Merck's Keytruda met goals in 1,100+ patients.
Bearish Signals
Citi downgraded stock to 'Sell' with $80 target due to high valuation.
Oncology success unlikely to support current price per Citi estimates.
Needs $26B annual oncology sales to justify ~$200 share price.
Moderna Inc. reported strong second-quarter 2026 financial results, generating revenue of USD 145.00 million against a consensus estimate of USD 102.93 million, representing a significant beat. The company also posted earnings per share (EPS) of USD -1.97, which exceeded the estimated loss of USD -2.03...
Bullish Signals
Q2 2026 revenue hit USD 145M, beating USD 102.93M consensus.
EPS beat estimates with a loss of USD -1.97 vs -2.03.
Bearish Signals
Stock trades at $182.11, nearly 58% above analyst target.
Company remains loss-making with quarterly EPS of -$1.97.
Moderna Inc (MRNA) reported Q1 2026 revenue of $400 million, representing a significant $300 million year-over-year increase, with costs of sales rising to $955 million primarily due to an $878 million litigation settlement related to Arbutus and Genevant. On a GAAP basis, the company recorded...
Bullish Signals
Revenue grew $300 million year-over-year to $400 million in Q1 2026, demonstrating strong commercial traction.
R&D expenses decreased by 24% and SG&A expenses dropped 18%, indicating improved operational efficiency despite the net loss.
Moderna maintains a robust cash position with $7.5 billion in cash and investments, providing ample liquidity for growth initiatives.
The company achieved a strategic milestone with mCOMBRIAX approval in the European Union, opening new market opportunities.
Revenue guidance anticipates up to 10% growth for 2026, signaling continued expansion beyond the current quarter.
Moderna secured approvals for Spikevax in the European Union, driving expected growth in the EU market for 2027.
The Phase 3 clinical trial for intismeran in non-small cell lung cancer has officially begun, diversifying the pipeline into oncology.
Management remains optimistic about future outcomes, noting they are "confident" regarding the litigation appeal and see no need to record a charge yet.
A second UK delivery campaign is planned for the fall, potentially creating a double year of deliveries and boosting revenue in Q3/Q4.
Early-stage disease focus with monotherapy safety profiles looks promising for preventing relapse, opening avenues for potential cures.
Phase 2 studies for RCC and muscle invasive bladder cancer are fully enrolled, positioning these assets to move quickly toward registrational studies if data is favorable.
Bearish Signals
The company reported a significant net loss of $1.3 billion on a GAAP basis in Q1 2026, primarily driven by an $878 million litigation settlement.
Moderna faces potential additional liability of up to $1.3 billion if it does not prevail in its appeal regarding the litigation settlement with Arbutus and Genevant.
A significant portion of Cost of Sales ($955 million) is attributed to litigation settlements rather than direct product costs, potentially distorting profitability metrics.
GuruFocus has detected 4 Warning Signs for MRNA, indicating potential undisclosed risks or financial vulnerabilities.
Revenue guidance for Q2 2026 ranges between $50 million and $100 million, representing a substantial deceleration compared to the $400 million generated in Q1 2026.
The company anticipates potential future declines in COVID vaccination rates, which poses a direct threat to revenue growth forecasts.
Revenue is heavily skewed geographically, with 80% coming from international markets and only 20% from the United States, increasing exposure to foreign exchange and regulatory risks abroad.
The resolution timeline for the $1.3 billion litigation charge could extend into late 2027 or 2028, creating prolonged uncertainty over future cash flows.
Moderna (MRNA) stock has surged 750% in 2026, driven primarily by the success of its personalized melanoma vaccine, Intsimeran, developed in partnership with Merck. The collaboration achieved its main Phase 3 trial goals, demonstrating a 42% reduction in the risk of recurrence or death compared...
Bullish Signals
Stock surged 750% in 2026 after melanoma vaccine success.
Q3 revenue rose 29% to $1.31B with $162M profit.
Trial showed 42% lower recurrence/death risk vs Keytruda.
CEO sees mechanism extending to kidney and bladder cancer.
Raised 2026 growth outlook to 15%-25%.
Bearish Signals
Trades at 45x forward sales vs 8.1x historical average.
Analyst price target of $153 implies significant downside.
Moderna (MRNA) shares rose 5.3% on November 6, 2026, following the release of strong third-quarter results and a raised revenue outlook for the full year. The company reported Q3 revenue of $1.3 billion, significantly beating analyst expectations of $890.3 million, driven primarily by higher COVID-19...
Moderna (MRNA) shares surged 8% following early clinical data for its experimental multiple myeloma therapy, mRNA-2808. The Phase 1/2 trial demonstrated the platform's ability to instruct cells to produce three T-cell engagers simultaneously, achieving four confirmed responses among 11 heavily pretreated patients. Notably, all three...
Bullish Signals
Shares surged 8% after mRNA-2808 achieved four responses in 11 patients.
Platform produced three simultaneous T-cell engagers with all targets detected.
mRNA-2808 showed no dose-limiting toxicities unlike approved competitors.
Moderna Inc. (NASDAQ:MRNA) experienced a dramatic 175% surge in its stock price during the third quarter, driven primarily by a landmark late-stage clinical trial success for its combined therapy candidate targeting melanoma. The study demonstrated that combining Moderna's mRNA-based cancer treatment with Merck's Keytruda achieved...
Bullish Signals
Stock jumped 174.98% in three months ending September.
Achieved first positive phase 3 readout for mRNA cancer treatment.
Received FDA approval for updated Spikevax and mNEXSPIKE formulas.
Set to join Nasdaq 100 index on October 9, 2026.
Bearish Signals
Analysts prefer AI stocks over Moderna for faster returns.
Stock remains heavily shorted with significant bearish risk.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)